Background. This is a validation study comparing the European System for Cardiac Operative Risk Evaluation
(EuroSCORE) II with the previous additive (AES) and logistic EuroSCORE (LES) and the Society of Thoracic Surgeons’
(STS) risk prediction algorithm, for patients undergoing valve replacement with or without bypass in Pakistan.
Patients and Methods. Clinical data of 576 patients undergoing valve replacement surgery between 2006 and
2013 were retrospectively collected and individual expected risks of death were calculated by all four risk prediction
algorithms. Performance of these risk algorithms was evaluated in terms of discrimination and calibration.
Results. There were 28 deaths (4.8%) among 576 patients, which was lower than the predicted mortality of 5.16%,
6.96% and 4.94% by AES, LES and EuroSCORE II but was higher than 2.13% predicted by STS scoring system. For
single and double valve replacement procedures, EuroSCORE II was the best predictor of mortality with highest
Hosmer and Lemmeshow test (H-L) p value (0.346 to 0.689) and area under the receiver operating characteristic
(ROC) curve (0.637 to 0.898). For valve plus concomitant coronary artery bypass grafting (CABG) patients actual
mortality was 1.88%. STS calculator came out to be the best predictor of mortality for this subgroup with H-L
p value (0.480 to 0.884) and ROC (0.657 to 0.775).
Conclusions. For Pakistani population EuroSCORE II is an accurate predictor for individual operative risk in
patients undergoing isolated valve surgery, whereas STS performs better in the valve plus CABG group.
Aortic, EuroSCORE, Mitral, Pakistan, Society of Thoracic Surgeons, Valve
Financial support: None of the authors has financial interest related
to this study to disclose.
Hasanat Sharif Department of Cardiothoracic Surgery Private wing 2nd floor Aga Khan University Hospital Karachi 74800, Pakistan email@example.com
Share this Article
Related Content In Interventional Cardiology
FOREWORD – HEART INTERNATIONAL – VOLUME 17 ISSUE 1 – 2023
Heart International. 2023;17(1):1
Welcome to the latest issue of Heart International. This edition includes a range of articles on topics showcasing the latest advances in our understanding and treatment of cardiovascular disease. We begin with focus on the hereditary cardiac disorder, hypertrophic cardiomyopathy, which previously had a limited treatment options. However, with the approval of the myosin inhibitor, […]
Peri- and Post-procedural Anticoagulation with Left Atrial Appendage Occlusion Devices
Heart International. 2023;17(1):54–9 DOI: https://doi.org/10.17925/HI.2023.17.1.54
A significant proportion of patients with atrial fibrillation (AF) who have a high stroke risk are currently being treated with oral anticoagulation (OAC), including direct oral anticoagulants (DOACs) and vitamin K inhibitors (VKAs).1 It is well known that the increased risk of thromboembolic stroke in patients with AF is primarily due to left atrial appendage (LAA) […]
Outcomes of Prediabetes Compared with Normoglycaemia and Diabetes Mellitus in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
Heart International. 2023;17(1):45–53 DOI: https://doi.org/10.17925/HI.2023.17.1.45
The American Diabetes Association (ADA) defines prediabetes as glycated haemoglobin (HbA1c) 5.7–6.4% or fasting plasma glucose (FPG) 100–125 mg/dL or 5.6–6.9 mmol/L.1 Patients with prediabetes have up to a 70% chance of developing diabetes and a two-fold higher risk of cardiovascular disease than normoglycaemic patients. Studies show results varying from no association to a strong association […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!